Generic placeholder image

Current Neuropharmacology

Rome
(Italy)

">Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

General Review Article

Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals

Author(s): Ceren Hangül, Sibel Berker Karaüzüm , Esra Küpeli Akkol*, Devrim Demir-Dora, Zafer Çetin, Eyüp İlker Saygılı, Gökhan Evcili and Eduardo Sobarzo-Sánchez

Volume 19 , Issue 12 , 2021

Page: [2276 - 2295] Pages: 20

DOI: 10.2174/1570159X19666210726151924

Price: $65

Abstract

Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence. It is not a life-threatening disease; however, the progression of the disease extends over being wheelchair bound. Despite some drug trials continuing, including DUX4 inhibition, TGF-ß inhibition and resokine which promote healthier muscle, there is not an applicable treatment option for FSHD today. Still, there is a need for new agents to heal, stop or at least slow down muscle wasting. Current FSHD studies involving nutraceuticals as vitamin C, vitamin E, coenzyme Q10, zinc, selenium, and phytochemicals as curcumin or genistein, daidzein flavonoids provide promising treatment strategies. In this review, we present the clinical and molecular nature of FSHD and focus on nutraceuticals and phytochemicals that may alleviate FSHD. In the light of the association of impaired pathophysiological FSHD pathways with nutraceuticals and phytochemicals according to the literature, we present both studied and novel approaches that can contribute to FSHD treatment.

Keywords: Facioscapulohumeral muscular dystrophy, FSHD, natural compound, phytochemical, nutraceutical, skeletal muscle, dystrophy.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy